Lucerna will be presenting at the 3rd RNA-Targeted Drug Discovery Summit:
December 8-10, 2020
“Spinach splice sensor: a cell-based drug discovery platform for splicing-related diseases”
Date, December 9 ⋅ 1:00 PM
Presentation by Ryan O’Hanlon
Download talk slide Here
Please contact us if you would like to meet with us there. Hope to see you in there!
Lucerna, Inc. aims to be the industry leader in the development of RNA-based research and drug discovery reagents. Its motto of “making all RNA visible and druggable” reflects Lucerna’s mission to develop plug-and-play products that allow better imaging and detection of RNA, and high-throughput screening platforms that enable new drug discovery of previous intractable RNA targets. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Samie R. Jaffrey, M.D., Ph.D., at Weill-Cornell University, Lucerna has generated a collection of intellectual property, know-how, and trade secrets to strengthen its market position in this newly burgeoning RNA field. Through innovation and alliances, Lucerna plans to expand its product offerings into areas related to RNA-targeted therapeutics, epitranscriptomics, biomarker detection, and single-cell analysis. Lucerna is a privately held company headquartered in Brooklyn, NY. For more information about Lucerna, please visit lucernatechnologies.com.